The Regional Collaborating Committee on Tuberculosis Control and Care (RCC-TB). Second meeting, Copenhagen, Denmark, 11 November 2013

The Regional Collaborating Committee on Tuberculosis Control and Care (RCC–TB)

Second meeting Copenhagen, Denmark, 11 November 2013

ABSTRACT The Regional Collaborating Committee on Tuberculosis Control and Care (RCC –TB) was established in September 2011 in response to the endorsement by the 53 Member States of the WHO European Region of the Consolidated action plan to prevent and combat multidrug- and extensively-drug resistant tuberculosis in the WHO European Region 2011–2015 at the 63rd session of the Regional Committee for Europe. The second meeting of the RCC–TB steering group was held in Copenhagen, Denmark, on 11 November 2013, involving 34 participants (steering group members and observers, including 15 representatives from WHO country offices in the Region). The meeting was conducted in English and Russian with simultaneous translation and was organized to coincide with several regional meetings held during the same calendar week. This report briefly summarizes outputs from the presentations, plenary discussions and working-group sessions and indicates future actions.

Keywords BEST PRACTICES INTERAGENCY RELATIONS KNOWLEDGE, ATTITUDES, PRACTICE NATIONAL HEALTH PROGRAMS TUBERCULOSIS, EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS, MULTI-DRUG RESISTANT

Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe UN City, Marmorvej 51 DK-2100 Copenhagen Ø, Denmark Alternatively, complete an online request form for documentation, health information, or for permission to quote or translate, on the Regional Office web site (http://www.euro.who.int/pubrequest). © World Health Organization 2014 All rights reserved. The Regional Office for Europe of the World Health Organization welcomes requests for permission to reproduce or translate its publications, in part or in full. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products d oes not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The views expressed by authors, editors, or expert groups do not necessarily represent the decisions or the stated policy of the World Health Organization.

CONTENTS Page

1. Introduction ................................................................................................................... 1 1.1 Meeting objectives................................................................................................ 1 1.2 Expected outcomes .............................................................................................. 2 2. Opening 2 2.1 Review of final TOR .............................................................................................. 2 3. Synergies between the RCC–TB and other institutions and initiatives ................................. 3 3.1 The European Respiratory Society ......................................................................... 3 3.2 The Global Fund to Fight AIDS, Tuberculosis & Malaria ............................................ 3 3.3 Compendium of best practices in TB prevention, control and care ............................ 4 3.4 Challenges of civil society organization involvement in TB prevention, control and care .......................................................................................................................... 4 4. Comparative advantages and action plan for RCC–TB ........................................................ 5 4.1 Where the RCC–TB can make a difference .............................................................. 5 4.2 Action plan for the RCC–TB in 2014 ....................................................................... 6 5. Next steps and closing .................................................................................................... 8

Annex 1 Annex 2 Annex 3

………………………………………………………………………………………………………………………9 ……………………………………………………………………………………….……………………………11 ………………………………………………………………………………….…………………………………13

Background, scope and purpose .................................................................................. 9 Programme ............................................................................................................. 11 Participants ............................................................................................................. 13

Acronyms and abbreviations CCM CSO ERS EU GFATM MDR–TB M/XDR–TB NGO NTP RCC–TB RICC–TB TB TOR country coordinating mechanism civil society organization European Respiratory Society European Union Global Fund to Fight AIDS, Tuberculosis & Malaria multidrug-resistant TB multidrug- and extensively-drug resistant tuberculosis nongovernmental organization national tuberculosis programme Regional Collaborating Committee on Tuberculosis Control and Care Regional Interagency Collaborating Committee on Tuberculosis Control and Care tuberculosis terms of reference

1. Introduction The Regional Collaborating Committee on Tuberculosis Control and Care (RCC–TB) was established in September 2011 in response to the endorsement by the 53 Member States of the WHO European Region of the Consolidated action plan to prevent and combat multidrug- and extensively-drug resistant tuberculosis in the WHO European Region 2011–20151 at the 63rd session of the Regional Committee for Europe. The RCC–TB provides an interactive platform for stakeholders such as donors, technical agencies, professional societies and patient and community representatives to exchange information related to multidrug- and extensively-drug resistant tuberculosis (M/XDR–TB) responses and advocate for action. The RCC–TB comprises a steering group and a member network. Its mission is to work towards the achievement of universal access to evidence-based tuberculosis (TB) and M/XDR–TB prevention, diagnosis, treatment and care across the Region. Key objectives include:     strengthening involvement and fostering collaboration among national and international partners in TB and M/XDR–TB prevention, control and care; raising awareness about TB; advocating for resource mobilization; and facilitating exchange of best practices in TB and M/XDR–TB prevention, care and control.

The second meeting of the RCC–TB steering group was held in Copenhagen, Denmark, on 11 November 2013, involving 34 participants (steering group members and observers, including 15 representatives from WHO country offices in the Region). The meeting, which consisted of presentations, plenary discussions and working-group sessions, was conducted in English and Russian with simultaneous translation and was organized to coincide with several regional meetings held during the same calendar week (week 46).

1.1 Meeting objectives The objectives were to:    1

discuss measures and terms of reference (TOR) for establishing the RCC–TB network; present the methodology for, and lessons learned from, compiling the bestpractice examples; update members on key challenges to, and progress on, RCC–TB activities;

Consolidated action plan to prevent and combat multidrug- and extensively-drug resistant tuberculosis in the WHO European Region 2011–2015. Copenhagen: WHO Regional Office for Europe; 2011 (EUR/RC61/15 + EUR/RC61/Conf.Doc./8; http://www.euro.who.int/__data/assets/pdf_file/0007/147832/wd15E_TB_ActionPlan_111388.pdf, accessed 20 January 2014).

1

 

review implementation of RCC–TB-related components of the consolidated action plan and discuss challenges and the way forward; and discuss how to further synergize actions and activities to optimize contributions to TB prevention, care and control in the Region.

1.2 Expected outcomes It was anticipated that by the close of the meeting, participants would have:     agreed actions to establish the RCC–TB network; received an update on challenges to, and progress on, RCC–TB activities; reviewed progress towards implementation of RCC–TB-related components of the consolidated action plan and discussed challenges and the way forward; and discussed and agreed possible scenarios and the next steps for synergizing members’ contributions under the RCC–TB framework.

2. Opening Masoud Dara, WHO Regional Office for Europe, and Fanny Voitzwinkler, RCC–TB Chair, opened the meeting by welcoming participants, encouraging them to contribute actively to discussions and support the realization of the RCC–TB mission and objectives. The meeting objective of developing an action plan for the RCC–TB was stressed and contributions to its development were anticipated with interest. It was noted by a meeting participant that the work of the Collaborative Group on Training had been very valuable and that reference to training and education was lacking in the meeting agenda. The statement was acknowledged and participants were encouraged to consider during the working-group sessions how the RCC–TB could link to training and education activities in the Region. The Regional Office will reconvene meetings of the Collaborative Group on Training from 2014; its work and that of the RCC–TB are linked, and the respective chairs will discuss how the groups can support each other.

2.1 Review of final TOR Masoud Dara presented the finalized TOR for the RCC–TB and thanked members of the steering group for their contributions to its development. It was important to ensure links to the Berlin Declaration on Tuberculosis2 and the consolidated action plan in the finalization process. It was observed that since the first meeting of the RCC–TB steering group, the committee’s name and acronym had been changed from its original formulation of Regional Interagency Collaborating Committee (RICC–TB). The change had been made to ensure non-agency organizations and stakeholders (including ministries and other organizations not categorized as agencies) were not excluded from becoming part of the Committee and its network. The first meeting of the RCC–TB steering group in December 2012 agreed to change the original name of Regional Interagency 2

Berlin Declaration on Tuberculosis. Copenhagen: WHO Regional Office for Europe; 2007 (EUR/07/5061622/5; http://www.euro.who.int/__data/assets/pdf_file/0008/68183/E90833.pdf, accessed 20 January 2014).

2

Coordinating Committee to Regional Collaborating Committee to signal the Committee’s scope in collaborating and sharing, but not necessarily coordinating and aligning, the work of member organizations.

3. Synergies between the RCC–TB and other institutions and initiatives 3.1 The European Respiratory Society Francesco Blasi, President of the European Respiratory Society (ERS), gave a brief introduction to the ERS and its activities in relation to TB prevention, care and control in Europe. The society, which has 10 000 members worldwide, was founded in 1990 as a platform for exchanging knowledge. It plays an important role in providing educational resources and harmonizing education in respiratory medicine in Europe. ERS has a number of priorities related to TB, including       researching TB-related vaccines; reducing health inequalities within and between European Union (EU) Member States; developing cost-effective early diagnosis and screening for TB; developing the Forum for TB Elimination think tank to inform innovative approaches to TB control and elimination as part of the 2012/2013 presidential plan; working with WHO and the European Centre for Disease Prevention and Control on the Internet-based consilium for multidrug-resistant TB (MDR–TB) case and programme management;3 and editing a short 30-page version of the TB chapter in the European lung white book4 for policy-makers and other decision-makers (to be published in December 2013).

Francesco Blasi highlighted the importance of communication between TB communities and TB-related organizations. He welcomed collaboration between WHO and the RCC–TB and emphasized WHO’s excellent work in moving the ERS towards a stronger commitment to public health activities in TB: this area was not “natural” to the ERS and consequently depended on inputs from partners such as RCC–TB.

3.2 The Global Fund to Fight AIDS, Tuberculosis & Malaria Nicolas Cantau, Regional Manager for eastern Europe and central Asia of the Global Fund to Fight AIDS, Tuberculosis & Malaria (GFATM), briefly presented the main principles of the new GFATM funding model. He stressed that implications for the Region have yet to be defined, but that most countries in eastern Europe and central Asia will be eligible to apply. ERS/WHO. ERS/WHO – TB consilium [website]. Lausanne: ERS; 2014 (https://www.tbconsilium.org/, accessed 20 January 2014). 4 Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B, editors. European lung white book. Respiratory health and disease in Europe. Lausanne: ERS; 2013 (http://www.erswhitebook.org/, accessed 20 January 2014). 3

3

The specific challenges of M/XDR–TB in the Region create a need for the GFATM to develop a regional-specific funding strategy and prioritize the regional allocation of resources. Nicolas Cantau stressed that the GFATM will need inputs and advice from partners in the Region, particularly WHO, on developing this strategy. He therefore encouraged the Regional Office and the RCC–TB to contribute actively to GFATM discussions and priority-setting work. He expressed the hope that the RCC–TB, Technical Advisory Group for Tuberculosis Control and WHO/GFATM meetings that were scheduled for the same week would contribute to these discussions.

3.3 Compendium of best practices in TB prevention, control and care Martin van den Boom of the Regional Office presented the recently published compendium of best practices in drug-resistant TB prevention, control and care.5 The best practices were collected over a three-month period in the summer of 2013 and cover issues such as policy, financing, partnership, capacity-building, service delivery and advocacy in TB prevention, care and control. Eighty-two examples from 30 countries were submitted: 8240 were selected by an expert committee, based on a set of criteria. The collection is intended to be an ongoing endeavour; successful projects or initiatives that may be applicable in other countries or settings in the Region can be submitted to WHO. All submissions will be available on a WHO-administered share-point or tool for storing and sharing e-information. It is hoped that this will become an important forum within which progress and ideas relating to the RCC–TB goals can be shared.

3.4 Challenges of civil society organization involvement in TB prevention, control and care Fanny Voitzwinkler, Chair of the RCC–TB steering group and representing the TB Europe Coalition, gave a brief presentation on some of the main challenges of civil society organization (CSO) involvement in TB prevention, control and care in the Region. She reported on a regional mapping exercise completed in 2013 and the creation of the Global Coalition of TB Activists and regional CSO platforms. Some of the main challenges faced by CSOs in Europe relate to:       funding; human resources, knowledge and training; lack of political will; human rights and stigma; stakeholders’ awareness of TB, advocacy and CSOs; support for networking and campaigning;

5

Best practices in prevention, control and care for drug-resistant tuberculosis. A resource for the continued implementation of the consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO European Region, 2011 –2015. Copenhagen: WHO Regional Office for Europe; 2013 (http://www.euro.who.int/en/health-topics/communicablediseases/tuberculosis/publications/2013/best-practices-in-prevention,-control-and-care-for-drug-resistanttuberculosis, accessed 20 January 2014).

4

 

difficulties for CSOs in contributing to the provision of anti-TB drugs and treatments; and the general population’s awareness of TB.

Based on the mapping exercise, the main recommendations to the regional network are to:      improve network members’ knowledge and skills and build their capacity; improve funding to compensate (at least partially) costs that members incur through networking; sustain network members’ motivation by using a strategic and focused approach that leads to tangible outcomes for them; intensify efforts to mobilize TB resources; and facilitate the use of Russian and English in correspondence and communications.

She ended by presenting the TB Europe Coalition’s expectations to RCC–TB. These include:      joint promotion of high-level TB advocacy by, for instance, using the EU as a platform; increasing domestic and regional political commitment; involving CSOs in TB care and control; encouraging GFATM support in terms of engagement and funding; and responding to specific country emergencies.

4. Comparative advantages and action plan for RCC–TB 4.1 Where the RCC–TB can make a difference Participants at an interactive working-group session brainstormed challenges in TB prevention, control and care for which the RCC–TB can offer advantages over other agencies and organizations and help to make a difference. After developing a list of key challenges relevant to the RCC–TB, the three most important were selected through a simple voting process. The prioritized and other identified challenges are shown in Box 1. In addition to the challenges set out in Box 1, there was also a perceived need to improve communication about TB. “Making the TB problem more attractive” was cited as a key factor in attracting donors and raising political awareness of the disease and its impacts and consequences at national and individual levels. The RCC–TB may be able to contribute to this task: there was wide agreement that it provides a good platform for collecting and sharing best practices and patient stories in TB prevention, care and control that can be used for advocacy purposes. The need for stronger eastern Europe representation on the steering group presented an internal challenge for the RCC–TB that ought to be addressed. Finally, it was suggested that the RCC–TB annually outline gaps in the field and set, re-evaluate and rethink its priorities.

5

Box 1. Challenges where the RCC–TB can make a difference Prioritized challenges The RCC–TB can make a difference in the priority areas of:  ensuring country ownership and high-level political advocacy, with the RCC–TB contributing to increasing consciousness about TB, forming strategies defining what is being advocated and tracking and responding to changing financing mechanisms;  creating better synergies with HIV and other health communities; and  identifying gaps in health care systems (psychosocial support, and knowledge, attitudes and practice), including access to vulnerable groups and migration challenges (unified patient system). Other challenges Defined challenges in other areas were:      relations between governments and nongovernmental organizations (NGOs) and CSOs (including information about services NGOs and CSOs provide and the potential for cooperation); increasing the quality of TB-related services; the absence of CSOs and the need for better coordination and more sustainability (creating platforms at country level); the need for greater sharing, coordination and collaboration among agencies (with the RCC–TB acting as a platform for focused technical discussions); and the lack of a collective partnership representing NGOs to donor institutions (including the GFATM).

4.2 Action plan for the RCC–TB in 2014 Having identified the three main TB challenges in which the RCC–TB can make a difference, participants split into working groups to further consider how the RCC–TB could play a role in addressing the challenges and develop an action plan for the relevant areas. Some cross-cutting actions were proposed as part of a RCC–TB action plan for 2014. These included:     creating a web platform for the RCC–TB to facilitate collaboration and exchange of experience, best practice, patient stories and other useful material for partners; increasing awareness about the RCC–TB and encouraging potential partners and interest groups to join the network; developing a factsheet on the RCC–TB to be shared with partners;6 and compiling an inventory on the RCC–TB web platform providing an overview of who is doing what in TB, based on a general mapping of actors, donors, CSOs and NGOs in TB at regional and national levels.

4.2.1 Action plan for advocacy activities The group agreed that there was a need to help organizations to be more vocal at high level. It was therefore suggested that RCC–TB, its members and network partners contribute to:

6

Sevim Ahmedov, United States Agency for International Development, and Gerard de Vries, Koninklijke Nederlandse Chemische Vereniging [Royal Netherlands Chemical Society], volunteered to develop a first draft of the factsheet by mid-December 2013.

6

      

developing media training for national tuberculosis programme (NTP) managers, avoiding duplication of, but being complementary to, the training offered at the International Union against Tuberculosis and Lung Disease congress; developing factsheets to be used as advocacy material to demonstrate effective TB control and care measures (including ambulatory care); composing a joint letter to the EU on the TB situation in the Region and its consequences; recommending brief prioritized advocacy messages for critical interventions; involving new sectors and donors in the Region, including the World Bank; prioritizing key materials to be made available in Russian translation, with links through the RCC–TB web platform; and making use of upcoming events and opportunities, such as: o World TB Day in March 2014 (one idea raised was to co-organize an event with colleagues from the Koch-Mechtnikov Forum in Berlin, Germany); o the International Union against Tuberculosis and Lung Disease meeting in Sofia, Bulgaria in June 2014 by encouraging Bulgarian politicians to attend (the NTP managers’ meeting is tentatively planned for the day before).

4.2.2 Action plan for improving synergies with HIV communities It was agreed that there was a need to increase awareness levels of the shared challenges and interactions between TB and HIV at all levels. It was therefore suggested that RCC–TB, its members and network partners contribute to:        increasing awareness of TB and HIV issues at all levels; developing a short (one-page) information sheet on TB and HIV in the Region; sharing and disseminating best practice on integrated models of TB and HIV with country cases (using the RCC–TB web platform); mapping current synergies and activities in the Region, including patient groups; bringing TB and HIV stakeholders together at conferences and other events organised by the RCC–TB and member institutions; supporting the establishment of a technical working group on TB and HIV under the national country coordinating mechanism (CCM); and encouraging CCM members to join the RCC–TB network.

4.2.3 Action plan for addressing gaps in the TB health care system for vulnerable populations It was suggested that the RCC–TB, its members and network partners contribute to:      continuing the expansion of the collection of best practices compiled and published by the Regional Office; communicating, sharing and disseminating best practice examples using the RCC–TB web platform; bringing additional relevant technical expertise on board with the RCC–TB; motivating countries, programmes and projects that are already working with vulnerable populations to gather and share positive experiences and best practices; and encouraging the use of social media to bring experiences closer to end-users. 7

5. Next steps and closing After lively discussion and suggestions for the way forward for the RCC–TB, Masoud Dara summarized the main conclusions of the meeting and the immediate next steps to be taken. These were to:     finalize the RCC–TB action plan with timelines develop the factsheet on the RCC–TB to be shared with partners develop milestones for the RCC–TB based on the action plan begin to organize regular three-monthly online meetings of the RCC–TB.

It was agreed that appointing a focal person from the steering group and having specific countries acting as leaders for each RCC–TB activity would be helpful to achieving goals and setting targets. Nominations for the position of vice-chair would be solicited, with votes being cast online. The meeting closed with thanks to the participants for their discussions and constructive contributions. All were encouraged to spread the news about the RCC–TB and inspire ministries, partners and NGOs to join the network.

8

Annex 1

BACKGROUND, SCOPE AND PURPOSE Background The WHO Regional Director for Europe established the Regional Collaborating Committee on Tuberculosis Control and Care (RCC–TB) in September 2011 in response to the endorsement by the 53 Member States of the WHO European Region of the Consolidated action plan to prevent and combat multidrug- and extensively-drug resistant tuberculosis in the WHO European Region 2011–20157at the 63rd session of the Regional Committee for Europe in Baku, Azerbaijan. The RCC–TB provides an interactive platform for stakeholders such as donors, technical agencies, professional societies and patient and community representatives to exchange information related to multidrug- and extensively-drug resistant tuberculosis (M/XDR–TB) responses and advocate for action. The RCC–TB comprises a steering group and a member network. The RCC–TB steering group consists of national and international partners engaged in tuberculosis (TB) prevention, care and control in the WHO European Region, who are dedicated to:      strengthening involvement and fostering collaboration among all stakeholders in the fight against TB; advocating for resource mobilization for TB; establishing a common platform to share best practices on TB and multidrug-resistant TB (MDR–TB) prevention and control; creating greater public, private and government awareness of TB as a public health threat; and accelerating and intensifying the involvement of civil society and NGOs to help alleviate TB-related morbidity, render TB care more patient-friendly and person-centred and reduce the burden of TB.

The RCC–TB network is an inclusive body comprising relevant stakeholders involved in TB prevention and control, including technical and funding agencies, civil society and professional organizations, medical professionals and representatives of philanthropic foundations, as well as community/patient representatives with substantial expertise and experience in areas related to TB prevention, control and care. Its overall mission is to help achieve universal access to evidence-based TB and M/XDR–TB prevention, diagnosis, treatment and care across the WHO European Region. The RCC–TB meeting was held in Copenhagen, Denmark, on 11 November 2013 and was organized back-to-back with a meeting of the Technical Advisory Group to the WHO European Region on 12 November 2013.

7

Consolidated action plan to prevent and combat multidrug- and extensively-drug resistant tuberculosis in the WHO European Region 2011–2015. Copenhagen: WHO Regional Office for Europe; 2011 (EUR/RC61/15 + EUR/RC61/Conf.Doc./8; http://www.euro.who.int/__data/assets/pdf_file/0007/147832/wd15E_TB_ActionPlan_111388.pdf, accessed 20 January 2014).

9

Specific objectives of the meeting Specific objectives were to:      discuss measures and terms of reference (TOR) for establishing the RCC–TB network; present the methodology for, and lessons learned from, compiling the best practice examples; update members on key challenges and progress regarding key RCC–TB activities; review implementation of RCC–TB-related components of the consolidated action plan and discuss challenges and the way forward; and discuss how to further synergise actions and activities to optimize contributions to TB prevention, care and control in the Region.

Expected outcomes It was anticipated that by the close of the meeting, participants would have:     agreed actions to establish the RCC–TB network; received an update on challenges and progress regarding key activities relating to the RCC–TB; reviewed progress towards implementation of RCC–TB-related components of the consolidated action plan and discussed challenges and the way forward; and discussed and agreed possible scenarios and the next steps for synergizing members’ contributions under the RCC–TB framework.

Methods The meeting programme included presentations and plenary discussions. The working languages were English and Russian, with simultaneous translation provided. Background documents  Consolidated action plan to prevent and combat multidrug- and extensively-drug resistant tuberculosis in the WHO European Region 2011–2015.  Best practices in prevention, control and care for drug-resistant tuberculosis. A resource for the continued implementation of the consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO European Region, 2011– 2015.8 Venue United Nations (UN) City, Marmorvej 51, DK 2100 Copenhagen Ø, Denmark Participants The meeting was attended by members of the RCC–TB steering group. Facilitators RCC–TB steering group chair: Ms Fanny Voitzwinkler WHO Regional Office for Europe: Dr Masoud Dara, Dr Martin van den Boom

8

Best practices in prevention, control and care for drug-resistant tuberculosis. A resource for the continued implementation of the consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO European Region, 2011 –2015. Copenhagen: WHO Regional Office for Europe; 2013 (http://www.euro.who.int/en/health-topics/communicable-diseases/tuberculosis/publications/2013/best-practices-inprevention,-control-and-care-for-drug-resistant-tuberculosis, accessed 20 January 2014).

10

Annex 2

PROGRAMME

Monday 11 November 2013 Zsuzsanna Jakab (WHO Regional Director for Europe) and Hans Kluge (Director, Division of Health Systems and Public Health, WHO Regional Office for Europe, and Special Representative of the Regional Director on M/XDR-TB) Masoud Dara (Programme Manager, Tuberculosis and M/XDR–TB, WHO Regional Office for Europe) Lucica Ditiu (Executive Secretary of the Stop TB Partnership)

09:00– 09:20

Opening remarks

09:20– 09:30 09:30– 09:50

RCC–TB review of finalized TOR

Stop TB Partnership: overview of progress, challenges in TB control, linkages and synergies with RCC–TB

09:50– 10:10 10:10– 10:30 10:50– 11:10 11:10– 11:25

Role of the European Respiratory Society in TB prevention, care and control in Europe and synergies with RCC–TB Possible input or advice of RCC–TB for Global Fund to Fight AIDS, Tuberculosis & Malaria TB concept note development process regarding CSO and NGO involvement Discussion

Francesco Blasi (President of the European Respiratory Society) Nicolas Cantau (Regional Manager for eastern Europe and central Asia, Global Fund to Fight AIDS, Tuberculosis & Malaria)

Compendium of best practices in TB prevention, control and care and its linkages with RCC–TB

Martin van den Boom, Technical Officer, Tuberculosis & M/XDR-TB, WHO Regional Office for Europe)

11:25– 11:40

Challenges of CSO involvement in TB prevention, control and care in the WHO European Region: an overview

Fanny Voitzwinkler (Chair, RCC–TB)

11:40– 12:10

Working-group session I Comparative advantage/added value of RCC–TB: where can RCC–TB make a difference?

Fanny Voitzwinkler Masoud Dara Martin van den Boom

12:10– 12:30

Working group session I Group presentations and plenary discussion

Fanny Voitzwinkler Masoud Dara Martin van den Boom

Working group session II

Fanny Voitzwinkler

11

13.30– 14:10 14:10– 14:30

Action plan for RCC–TB detailing flagship interventions

Masoud Dara Martin van den Boom Fanny Voitzwinkler Masoud Dara Martin van den Boom

Working group session II Group presentations and plenary discussion Discussion: RCC–TB action plan, definition of outputs, organizational matters, funding, communication, link between steering group and RCC–TB network

14.30– 15:15

Fanny Voitzwinkler Masoud Dara Martin van den Boom

15:45– 16:45 16:45– 17:00

Formulation of next steps, summary of discussions Closure of the meeting

Fanny Voitzwinkler Masoud Dara Hans Kluge Masoud Dara

12

Annex 3

PARTICIPANTS Members Dr Sevim Ahmedov Senior TB Technical Advisor United States Agency for International Development Bureau for Global Health Office of Health, Infectious Diseases and Nutrition 1201 Pennsylvania Avenue, NW, Suite 200 Washington, DC 20004, United States of America Professor Francesco Blasi President, European Respiratory Society 2012/2013 Professor of Respiratory Medicine Vice-chairman, Department of Pathophysiology and Transplantation, Università degli Studi di Milano Chief UOC Broncopneumologia IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda Milano Via Francesco Sforza 35 20122 Milan, Italy Dr Nicolas Cantau Regional Manager eastern Europe and central Asia The Global Fund to Fight AIDS, Tuberculosis & Malaria Geneva Secretariat Chemin de Blandonnet 8 1214 Vernier, Geneva, Switzerland Dr Esther C. Casas HIV/TB advisor Médecins Sans Frontières – Operations Centre Amsterdam (MSF–OCA) Plantage Middenlaan, 14 1001 EA Amsterdam, Netherlands Dr Gerard de Vries Head, Regional Office The Netherlands & Europe KNCV Tuberculosis Foundation Parkstraat 17 P.O. Box 146 2501 CC Den Haag, Netherlands Ms Maria Paola Lia Programme Manager Eli Lilly Foundation Global Health Programs and Access Ch. des Coquelicots 16 CP 580, Air Centre 1214 Vernier, Geneva, Switzerland Tel.: +202 808 3895 E-mail: sahmedov@usaid.gov

Tel.: +390 250 320627 E-mail: francesco.blasi@unimi.it

Tel.: +41 58 791 1668 E-mail: nicolas.cantau@theglobalfund.org

Tel.: +31 20 520 8707 E-mail: Esther.CASAS@amsterdam.msf.org

Tel.: +31 70 416 7239 E-mail: deVriesG@kncvtbc.nl

Tel.: +41 22 306 0333 E-mail: lia_maria_paola@lilly.com

13

Dr Lilian Severin Director Health Development Center AFI 7, Varsovia St. MD–2060 Chisinau, Republic of Moldova Professor Timo Ulrichs Koch-Metschnikow-Forum Langenbeck-Virchow-Haus Luisenstraße 59 10117 Berlin, Germany Ms Fanny Voitzwinkler European Policy & Advocacy Manager Global Health Advocates TB Europe Coalition Coordinator Secretariat of the European Parliament Working Group on Innovation, Access to Medicines and Poverty-Related Diseases MUNDO-B, 26 rue d'Edimbourg B-1050 Brussels, Belgium Ms Maja Volland Coordinator Stop-TB Forum Stop-TB Forum Luisenstr. 58/59 10117 Berlin, Germany WHO Regional Office for Europe Dr Andrei Dadu Technical Officer Tuberculosis & M/XDR–TB Dr Masoud Dara Programme Manager Tuberculosis & M/XDR–TB Dr Pierpaolo de Colombani Medical Officer Tuberculosis & M/XDR–TB Dr Hans Kluge Director Health Systems and Public Health Special Representative of the Regional Director on M/XDR–TB Dr Kristin Kremer Scientist Tuberculosis & M/XDR–TB

Tel.: +373 022 600 489 E-mail: lseverin@afi.md

Tel.: +49 030 809233215 E-mail: timo.ulrichs@akkonhochschule.de

Tel.: +32 0 2 893 1051 E-mail: fvoitzwinkler@ghadvocates.org

Tel.: +49 30 700 130 192 E-mail: maja.volland@stop-tb.de

Tel.: +45 45 33 6609 E-mail: dad@euro.who.int

Tel.: +45 45 33 6649 E-mail: mdd@euro.who.int

Tel.: +45 45 33 6650 E-mail: pco@euro.who.int

Tel.: +45 45 33 6744 E-mail: hkl@euro.who.int

Tel.: +45 45 33 6752 E-mail: kkr@euro.who.int

14

Ms Elizabeth Neville Programme Assistant Tuberculosis & M/XDR–TB Ms Oleksandra Perepelytsia Secretary Tuberculosis & M/XDR–TB Dr Guénaël Rodier Director Communicable Diseases, Health Security & Environment Dr Martin van den Boom Technical Officer Tuberculosis & M/XDR–TB WHO country offices Dr Gayane Ghukasyan National Professional Officer WHO Country Office, Armenia Dr Javahir Suleymanova National Professional Officer WHO Country Office, Azerbaijan Dr Valiantsin Rusovich National Professional Officer WHO Country Office, Belarus Dr Nino Mamulashvili National Professional Officer WHO Country Office, Georgia Mr Szabolcs Szigeti National Professional Officer WHO Country Office, Hungary Dr Aliya Kosbayeva Health Officer WHO Country Office, Kazakhstan Ms Saliya Karymbaeva Country Programme Officer WHO Country Office, Kyrgyzstan Dr Silviu Ciobanu Country Programme Officer WHO Country Office, Republic of Moldova Dr Cassandra Butu National Professional Officer WHO Country Office, Romania

Tel.: +45 45 33 6791 E-mail: ene@euro.who.int

Tel.: +45 45 33 6726 E-mail: pea@euro.who.int

Tel.: +45 45 33 6686 E-mail: gur@euro.who.int

Tel.: +45 45 33 6610 E-mail: mva@euro.who.int

Tel.: +374 105 12001 E-mail: gghukasyan@who.am

Tel.: +994 50 216 5180 E-mail: suleymanovaj@euro.who.int

Tel.: +375 44 794 1041 E-mail: ruv@euro.who.int

Tel.: +995 32 99 8073 E-mail: nma@euro.who.int Tel.: +36 1 328 6082 E-mail: szs@euro.who.int

Tel.: +7 7172 696534/5 E-mail: kosbayevaa@euro.who.int

Tel.: +996 312 61 2677 E-mail: sak@euro.who.int

Tel.: +373 22 839 972 E-mail: cis@euro.who.int

Tel.: +40 21 2017888 E-mail: butuc@euro.who.int

15

Dr Dmitry Pashkevich National Professional Officer WHO Country Office, Russian Federation Dr Sayohat Hasanova National Professional Officer WHO Country Office, Tajikistan Dr Bogdana Shcherbak-Verlan Technical Officer, Communicable Diseases WHO Country Office, Ukraine Dr Andrej Slavuckij Medical Officer, TB, MDR–TB WHO Country Office, Ukraine Dr Jamshid Gadoev National Professional Officer WHO Country Office, Uzbekistan Dr Ogtay Gozalov Medical Officer WHO Country Office, Uzbekistan Interpreters Ms Tatiana Polunina 22, 2 Ferganskiy proezd 109507 Moscow, Russian Federation Ms Lyudmila Yurastova 29, Angarskaya Street, Apt. 71 125412 Moscow, Russian Federation Rapporteur Ms Nina Bjerglund Andersen Kommanderiestrasse 8 53111 Bonn, Germany

Tel.: +998 71 281 5172 E-mail: d.pashkevich@whorussia.org

Tel.: +992 48 701 1472 E-mail: shasanova.who@tajnet.tj

Tel.: +380 44 425 8828 E-mail: bsv@euro.who.int

Tel.: +380 44 425 8828 E-mail: sla@euro.who.int

Tel.: +998 71 281 5172 E-mail: jag@euro.who.int Tel.: +998 71 281 5172 E-mail: ogo@euro.who.int

Tel.: +7 910 3071087 E-mail: tpolunina@inbox.ru Tel.: +7 903 833 37 86 E-mail: vlad@mila.elcom.ru

Tel.: +49 176 983 254 70 E-mail: ninabjerglund@gmail.com

16